4Roberson ED, Scearce Levie K, Palop JJ, et al. Reducing en dogenous tau ameliorates amyloid beta-induced deficits in an Alzheimer's disease mouse model[J].Science, 2007, 316 (5825) :750-754.
5Hoozemans JJ, Veerhuis R, Van Haastert ES, et al. The unfolded protein response is activated in Alzheimer's disease[J].Acta Neuropathol(Berl) ,2005,110(2) : 165 -172.
6Scheff SW, Price DA, Schmitt FA, et al. Synaptic alterations in CA1 in mild Alzheimer disease and mild cognitive impair ment[J].Neurology,2007,68(18) : 1501-1508.
7Garzon DJ, Fahnestock M. Oligomeric amyloid decreases bas al levels of brain derived neurotrophic factor(BDNF)mRNA via specific downregulation of BDNF transcripts IV and V in differentiated human neuroblastoma cells [J] .J Neurosci, 2007,27(10) :2628 -2635.
8Nagahara AH, Merrill DA, Coppola G, et al. Neuroprotective effects of brain-derived neurotrophie factor in rodent and primate models of Alzheimer's disease[J]. Nat Med, 2009,15 (3) :331-337.
9Gouras GK,Almeida CG,Takahashi RH. Intraneuronal Abe ta accumulation and origin of plaques in Alzheimer's disease[J]. Neurobiol Aging,2005,26(9):1235-1244.
10Cardoso SM, Santana I, Swerdlow RH, et al. Mitochondria dysfunction of Alzheimer's disease cybrids enhances Abeta toxicity[J]. J Neurochem,2004,89(6) :1417- 1426.
6[1]Strittmatter W J,Saunders A M,Schmechel D,et al.Apolipoprotein E:high-avidity binding to beta-amyloid and increased frequency of type 4 allele in late-onset familial Alzheimer disease[J].Proc Natl Acad Sci USA,1993,90(5):1977-1981.
7[2]Corder E H,Saunders A M,Strittmatter W J,et al.Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer's disease in late onset families[J].Science,1993,261(5123):921-923.
8[4]Citron M,Westaway D,Xia W,et al.Mutant presenilins of Alzheimer's disease increase production of 42-residue amyloid beta-protein in both transfected cells and transgenic mice[J].Nat Med,1997,3(1):67-72.
9[7]Torreilles F,Touchon J.Pathogenic theories and intrathecal analysis of sporadic form of Alzheimer's disease[J].Prog Neuroboil,2002,66(3):191-203.
10[8]Wang J Z,Grundke-Iqbal I,Iqbal K.Glycosylation of microtubule-associated protein tau:an abnormal posttranslational modification in Alzheimer's disease[J].Nat Med,1996,2(8):871-875.
5Launer LJ, Andersen K, Dewey ME, et al. Rates and risk factors for dementia and Alzheimer's disease., results from EURODEM pooled analyses. EURODEM Incidence Research Group and Work Groups.European Studies of Dementia [J]. Neurology, 1999, 52 (1) :78- 84.
6Armstrong RA. The molecular biology of senile plaques and neu- rofibrillary tangles in Alzheimer's disease[J].Folia Neuropathol, 2009,47 (4) : 289-299.
7Simons M, Schwarzler F, Lutiohann D,et al.Treatment with sim- vastatin in norrmocholesterolemic patients with Alzheimer's dis- ease: a 26-week randomized, placebo-controlled, double-blind trial [J ]. Ann Neurol, 2002,52 (3) : 346-350.
8Mackenzie IR, Moon DG. No steroid anti-inflarnmatory drug use and Alzheimer-type pathology in aging[J]. Neurology, 2000, 54 (3) :732-734.
9Rogers JT, Lahirri DE. Metal and inflammatory targets for Alzheimefs disease[J].Curr Drug Targets, 2004,5(6):535- 551.
10Cherny RA, Atwood CS,Xilinas ME, et al. Treatment with a cop- per-zinc chelator markedly and rapidly inhibits beta-amyloid accu- mulation in Alzheimer's disease transgenic mice[J]. Neuron, 2001,30(3) :665- 676.
